Checkpoint Therapeutics, Inc.

Quarterly Report for period ending 2023-09-30

Quarterly Report for period ending 2023-06-30

Quarterly Report for period ending 2023-03-31

Annual Report for period ending 2022-12-31

Quarterly Report for period ending 2022-09-30

Quarterly Report for period ending 2022-06-30

Quarterly Report for period ending 2022-03-31

Annual Report for period ending 2021-12-31

Quarterly Report for period ending 2021-09-30

Quarterly Report for period ending 2021-06-30

Current report filing

Current report filing

Current report filing

Current report filing

Current report filing

Current report filing

Current report filing

Current report filing

Current report filing

Current report filing

Exempt (Private) Offering

Notice of Effectiveness

A correspondence can be sent as a document with another submission type or can be sent as a separate submission.

Notice of Effectiveness

Notice of Effectiveness

Notice of Effectiveness

A correspondence can be sent as a document with another submission type or can be sent as a separate submission.

A correspondence can be sent as a document with another submission type or can be sent as a separate submission.

A correspondence can be sent as a document with another submission type or can be sent as a separate submission.

Exempt (Private) Offering

ARMISTICE CAPITAL, LLC: Major Shareholders

GRAY WILLIAM GARRETT: Statement of changes in beneficial ownership of securities

Oliviero James F III: Statement of changes in beneficial ownership of securities

Oliviero James F III: Annual statement of changes in beneficial ownership of securities

Fortress Biotech, Inc.: Statement of changes in beneficial ownership of securities

Fortress Biotech, Inc.: Statement of changes in beneficial ownership of securities

Fortress Biotech, Inc.: Major Shareholders

Fortress Biotech, Inc.: Major Shareholders

Fortress Biotech, Inc.: Statement of changes in beneficial ownership of securities

Bechon Christian: Statement of changes in beneficial ownership of securities

Prospectus filed pursuant to Rule 424(b)(5)

Initial registration statement for securities to be offered to employees pursuant to employee benefit plans

Registration statement for specified transactions by certain issuers

Prospectus filed pursuant to Rule 424(b)(5)

Prospectus filed pursuant to Rule 424(b)(5)

Registration statement for specified transactions by certain issuers

Prospectus filed pursuant to Rule 424(b)(5)

Registration statement for specified transactions by certain issuers

Registration statement for specified transactions by certain issuers

Prospectus filed pursuant to Rule 424(b)(5)

Definitive proxy statements

Preliminary proxy statement not related to a contested matter or merger/acquisition

Definitive information statements

Preliminary information statement not related to a contested matter or merger/acquisition

Definitive additional proxy soliciting materials including Rule 14(a)(12) material. Note: Submission type DEFA14A can be filed as part of Form 8-K. For filers subject to 8-K filing requirements, we recommend the use of the 8-K combined form type as the easiest method for fulfilling your filing requirement for both forms.

Definitive proxy statements

Definitive proxy statements

Definitive additional proxy soliciting materials including Rule 14(a)(12) material. Note: Submission type DEFA14A can be filed as part of Form 8-K. For filers subject to 8-K filing requirements, we recommend the use of the 8-K combined form type as the easiest method for fulfilling your filing requirement for both forms.

Preliminary proxy statement not related to a contested matter or merger/acquisition

Definitive additional proxy soliciting materials including Rule 14(a)(12) material. Note: Submission type DEFA14A can be filed as part of Form 8-K. For filers subject to 8-K filing requirements, we recommend the use of the 8-K combined form type as the easiest method for fulfilling your filing requirement for both forms.